1 week ago
1
PeopleImages/iStock via Getty Images
- IDEAYA Biosciences (NASDAQ:IDYA) and Servier, an independent international pharmaceutical group, have signed a licensing agreement to develop darovasertib, a treatment for a rare eye cancer.
- According to the deal, Servier will have the rights to regulate and sell darovasertib in all
English (US) ·